Share This Page
Suppliers and packagers for sumycin
✉ Email this page to a colleague
sumycin
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma Intl | SUMYCIN | tetracycline hydrochloride | TABLET;ORAL | 061147 | ANDA | Pharmaka Generics Inc. | 82644-087-60 | 60 TABLET, FILM COATED in 1 BOTTLE (82644-087-60) | 2024-01-19 |
| Strides Pharma Intl | SUMYCIN | tetracycline hydrochloride | TABLET;ORAL | 061147 | ANDA | Pharmaka Generics Inc. | 82644-870-60 | 60 TABLET, FILM COATED in 1 BOTTLE (82644-870-60) | 2024-01-19 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Sumycin (Tetracycline)
Introduction
Sumycin, known generically as tetracycline, is a broad-spectrum antibiotic used primarily for treating various bacterial infections, including respiratory tract infections, urinary tract infections, and certain sexually transmitted diseases. Since its discovery in 1948, tetracycline has become a staple in antibiotic treatments. Despite the advent of newer antibiotics, sumycin remains in production globally, with several suppliers across different regions. This report provides an in-depth analysis of current suppliers for sumycin, focusing on manufacturing companies, distribution channels, and market dynamics.
Overview of Sumycin (Tetracycline)
Tetracycline is a naturally occurring antibiotic derived from Streptomyces spp. bacteria. Its mechanism involves inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit. Regulatory agencies, including the FDA, have approved tetracycline formulations, though many regions have shifted toward newer derivatives with improved safety profiles.
Despite competition from semi-synthetic tetracyclines such as doxycycline and minocycline, sumycin remains available, primarily through generic manufacturers. Its production is subject to patent expiration, market demand fluctuations, and regulatory standards.
Global Suppliers of Sumycin
1. Major Pharmaceutical Manufacturers
a. Chinese Manufacturers
Key Players:
- North China Pharmaceutical Group Corporation (NCPC): A leading producer of tetracycline in China, known for its large-scale fermentation plants capable of producing bulk quantities of sumycin. NCPC supplies both domestic and international markets, often at competitive prices.
- Shandong Jining Ruidian Biological Technology: Specializing in fermentative antibiotics, with capacity for tetracycline production that meets GMP standards.
Market Dynamics:
Chinese manufacturers dominate the supply landscape, primarily due to lower manufacturing costs and extensive export networks to developing and developed countries. The Chinese government’s policies support bulk antibiotic exports, which help sustain global availability.
b. Indian Manufacturers
Key Players:
- Biological E. Limited: An established producer of tetracycline, supplying generic formulations globally.
- Serum Institute of India: While mainly known for vaccines, the company also manufactures antibiotics, including tetracycline, for supply within India and export markets.
Market Dynamics:
India’s generic antibiotic industry is highly regulated, with multiple companies adhering to WHO GMP standards, making India a significant vendor of sumycin to global markets.
c. European and North American Manufacturers
While less prominent, a few regional firms produce tetracycline formulations primarily for local markets or as custom contract manufacturing. However, these tend to focus on semi-synthetic or derivative antibiotics rather than natural tetracycline.
2. Contract Manufacturers and OEM Suppliers
Pharmaceutical companies often source active pharmaceutical ingredients (APIs) like tetracycline from contract manufacturing organizations (CMOs) specializing in fermentation-based antibiotic production. Major CMOs catering to sumycin include:
- Fujifilm Toyama Chemical (Japan): Known for fermentation and biopharmaceuticals, though primarily focused on specialty drugs.
- DEV Pharmaceutical (India): Specializes in manufacturing generic APIs, including tetracycline, for global clients under contract manufacturing agreements.
Distribution and Supply Chain Considerations
Global distribution channels for sumycin are heavily dependent on API suppliers and finished-dose manufacturers. Many companies source APIs from Chinese and Indian producers to meet cost and supply requirements, then assemble finished pharmaceutical products regionally.
Regulatory certifications such as GMP compliance, WHO prequalification, and FDA approvals are prerequisites for international supply chains, ensuring quality and regulatory acceptance.
Market Trends Influencing Supply
- Patent expirations of brand-name tetracyclines have led to increased production of generics, expanding supplier bases.
- Regulatory crackdowns on antibiotic overproduction in some regions can impact supply stability and pricing.
- Antibiotic stewardship programs and decreased demand for broad-spectrum antibiotics have led to fluctuating demand, affecting supplier investment.
Challenges Faced by Suppliers
- Regulatory hurdles including stringent environmental and safety standards for fermentation processes.
- Antimicrobial resistance (AMR): Growing resistance trends reduce demand, potentially impacting production levels.
- Market shifts toward newer, less toxic antibiotics have decreased the prominence of sumycin, influencing suppliers’ focus.
Conclusion
The primary suppliers of sumycin (tetracycline) are predominantly based in China and India, with established manufacturing capacities catering to global markets. While Chinese companies like NCPC lead in volume due to cost efficiencies, Indian enterprises such as Biological E. Limited also serve as significant suppliers. Other regional manufacturers supply smaller quantities, mainly for localized markets.
The continued availability of sumycin depends on market demands, regulatory environments, and ongoing competition from newer antibiotics. Businesses sourcing tetracycline should prioritize suppliers with robust GMP compliance, reliable distribution networks, and transparent manufacturing practices.
Key Takeaways
- Leading Suppliers: Chinese companies (e.g., NCPC), Indian manufacturers (e.g., Biological E.), dominate the sumycin supply chain.
- Market Dependency: Global supply heavily relies on Chinese and Indian API producers, with regional companies filling niche or localized demands.
- Regulatory Standards: Suppliers with GMP and WHO prequalification are preferred for international procurement.
- Market Dynamics: Patent expirations and rising antimicrobial resistance influence supply stability and strategic sourcing decisions.
- Future Trends: Increased regulation and market shifts toward newer antibiotics could impact availability and supplier focus.
FAQs
1. Are there any original patent holders for sumycin still manufacturing it?
No. The original patents for tetracycline expired in most jurisdictions decades ago, leading to widespread generic manufacturing.
2. Which regions dominate the production of sumycin APIs?
China and India dominate the API production landscape due to cost advantages and established fermentation facilities.
3. How important is GMP certification for suppliers of sumycin?
GMP certification is essential for suppliers intending to export to regulated markets such as the US, EU, and Japan, ensuring product quality and safety.
4. What impact does antimicrobial resistance have on sumycin supply?
Rising resistance reduces clinical demand, which may lead to lower production volumes and potentially decreased supplier focus on sumycin.
5. Can generic sumycin formulations differ significantly between suppliers?
Quality standards and formulations vary; selecting suppliers with international regulatory approvals reduces risk of substandard products.
References
[1] U.S. Food and Drug Administration. Tetracycline Hydrochloride Capsules, USP.
[2] World Health Organization. Prequalification of Medicines Program.
[3] MarketsandMarkets. Antibiotics Market - Global Forecast to 2027.
[4] Chinese Pharmaceutical Industry Reports. Annual Production and Export Data.
[5] Indian Pharmaceutical Alliance. Generic Antibiotics Production Report.
More… ↓
